Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDAC

Claire M. Pfeffer, Sydney J. Clifford, Saadia A. Karim, Ella Rose D. Chianis, Brittany N. Heil, Lauren E. Gartenhaus, E. Kay, Garima Baral, Elizabeth G. Hoffman, Sagar M. Utturkar, Harish Kothandaraman, Whitney R. Smith-Kinnaman, Kasi Hansen, Emily A. Smith, Emily Porter, Fuping Zhang, Nadia A. Lanman, Jukka Westermarck, Emma H. Doud, Amber L. Mosley, Jennifer P. Morton, Brittany L. Allen-PetersenbioRxiv 2025 · DOI

TL;DR

This study reveals a surprising dual role for the PP2A-B56α protein in pancreatic cancer (PDAC). While typically considered a tumor suppressor, activating PP2A-B56α in PDAC paradoxically fuels tumor growth by hijacking the EGFR signaling pathway, suggesting new therapeutic avenues that combine PP2A activation with EGFR inhibition.

What Problem Does This Paper Address?

Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with limited treatment options, largely driven by mutations in the KRAS gene. While KRAS mutations are well-established drivers, the complex signaling networks that sustain PDAC growth and resistance are not fully understood. Protein phosphatases, like Protein Phosphatase 2A (PP2A), are critical regulators of these signaling pathways, but their specific roles in PDAC are complex and context-dependent. Previous research indicated that PP2A can act as a tumor suppressor, but activating it in PDAC cell lines sometimes led to increased oncogenic signaling. This paper investigates the specific role of the PP2A-B56α subunit in PDAC, aiming to clarify its function and identify potential therapeutic targets, especially given the known importance of EGFR signaling in PDAC progression.

Methods

The researchers employed a multi-pronged approach:

  • Genetic Manipulation: They created PDAC cell lines with either a knockout (loss) or overexpression (gain) of the B56α subunit using CRISPR-Cas9 technology and lentiviral vectors.
  • Pharmacological Activation: They used a small molecule activator of PP2A, DT-061, which preferentially stabilizes B56α-containing PP2A complexes.
  • Cell-Based Assays: Standard assays were used to measure cell proliferation, clonogenic colony formation (ability to form colonies from single cells), soft agar colony growth (anchorage-independent growth, a hallmark of cancer), and cell migration.
  • RNA Sequencing (RNAseq): This technique was used to analyze changes in gene expression profiles in response to DT-061 treatment and B56α overexpression, identifying pathways that were activated or suppressed.
  • Proteomics and Phospho-proteomics: These techniques were used to analyze the global protein expression and the phosphorylation status of proteins, providing insights into signaling pathway activation and regulation.
  • In Vivo Studies: They utilized genetically engineered mouse models of PDAC (KPC mice) with conditional knockout of the PP2A inhibitor CIP2A to study the effects of chronic PP2A activation on tumor progression and survival. They also performed xenograft studies where PDAC cells were implanted into immunocompromised mice and treated with drugs.
  • Drug Combination Studies: They tested the synergistic effects of combining a PP2A activator (DT-061) with an EGFR inhibitor (Afatinib) in cell lines and in mouse models.
  • ELISA: This immunoassay was used to quantify the levels of specific EGFR ligands in cell culture media.
  • Western Blotting: Used to detect and quantify specific proteins, including phosphorylated EGFR.
  • Immunofluorescence: Used to visualize protein localization and expression in tissue samples.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Paradoxical Role of B56α: The most striking finding is that activating B56α, a subunit often associated with tumor suppression, actually promotes PDAC proliferation and tumorigenesis. This challenges the general understanding of PP2A's role and highlights the critical importance of subunit-specific functions.
  • Hijacking EGFR Signaling: The study identifies a novel mechanism where B56α activation leads to increased expression and processing of EGFR ligands (like AREG), which then drives EGFR signaling. This is a key insight because EGFR is a known driver of PDAC.
  • Non-Canonical Role: This suggests a "non-canonical" role for PP2A-B56α in PDAC, where instead of suppressing oncogenic pathways, it actively promotes them through EGFR.
  • Therapeutic Vulnerability: The findings reveal a potential therapeutic strategy: combining PP2A activation with EGFR inhibition. This combination showed synergistic effects in vitro and in vivo, reducing tumor growth.
  • Context-Dependent Function: The study emphasizes that PP2A's function is highly context-dependent, with B56α behaving differently in PDAC compared to other cancers or even other PP2A subunits.

Key Results

  • Loss of B56α reduces proliferation: Knocking out B56α in PDAC cell lines significantly reduced their proliferation and colony formation.
  • Overexpression of B56α increases tumorigenic phenotypes: Conversely, overexpressing B56α in PDAC cell lines led to increased proliferation, clonogenic growth, and soft agar colony growth. This effect was specific to B56α, as other PP2A B subunits did not show similar effects.
  • B56α activation upregulates EGFR signaling: Pharmacological activation of PP2A with DT-061 and B56α overexpression led to increased expression of EGFR ligands and subsequent activation of EGFR signaling.
  • EGFR is essential for B56α-driven proliferation: Knocking down EGFR or AREG significantly attenuated the increased proliferation caused by B56α overexpression.
  • Loss of CIP2A (PP2A inhibitor) reduces survival in vivo: In a mouse model, genetic loss of CIP2A (leading to chronic PP2A activation) accelerated PDAC progression and decreased overall survival, accompanied by increased EGFR phosphorylation.
  • Combination therapy is synergistic: The combination of DT-061 (PP2A activator) and Afatinib (EGFR inhibitor) showed synergistic anti-tumor effects in both cell lines and mouse models.

Limitations and Future Work

  • Cell Line Specificity: While the study used multiple PDAC cell lines, the response to PP2A signaling alterations varied, suggesting that not all PDAC cell lines or patients may respond uniformly. The authors note that PP2A activation did not alter AREG shedding in Capan2 or HPAFII cells, indicating subsets of PDAC cell lines are more sensitive.
  • Other PP2A Subunits: While the study focused on B56α, the authors acknowledge that CIP2A regulates multiple B56 family subunits, and its loss might impact other subunits, making the observed effects complex.
  • EGFR Ligand Specificity: While AREG was identified as a key ligand, the study was unable to detect other EGFR ligands (EGF, HB-EGF, EREG) from conditioned media, leaving open the question of their contribution.
  • Future Directions: The authors suggest further studies to investigate the dynamics of EGFR internalization and cellular fate in response to PP2A activation, as well as the role of other HER family proteins in these phenotypes. Understanding the interplay between CIP2A and PP2A during PDAC progression and the impact of high vs. low PP2A activity are also highlighted as important areas for future research.

Summary updated

Abstract

Pancreatic ductal adenocarcinoma (PDAC) stands to become the second most deadly cancer by 2030. The small GTPase, KRAS, is mutated in over 90% of PDAC patients and considered the primary driver mutation. Despite being an almost ubiquitous event, KRAS mutations have been difficult to target therapeutically, particularly KRAS <sup>G12D</sup> , the most common mutation in PDAC. In addition to these pharmacological challenges, KRAS mutations have been shown to drive signaling plasticity and therapeutic resistance through phosphorylation cascades in most cancers. Protein phosphatases are master regulators of kinase signaling, however the contribution of phosphatase deregulation to mutant KRAS cancer phenotypes is poorly understood. Protein phosphatase 2A (PP2A) inhibits effectors downstream of KRAS, placing this family of enzymes as key regulators of PDAC oncogenic signaling. However, our previous studies utilizing small molecule activating compounds of PP2A show a heterogeneous response in PDAC, with some cell lines displaying increased oncogenic signaling despite induction of phosphatase activity. Similarly, specific PP2A subunits exhibit both tumor suppressive and oncogenic functions depending on the cellular context. Therefore, understanding the role of PP2A in regulating cancer phenotypes is critical for the future development of therapeutic strategies that leverage this phosphatase. Here, we determined the impact of the specific PP2A subunit, B56α, on PDAC phenotypes using both genetic and pharmacological activation strategies in human PDAC cell lines and genetic mouse models. We demonstrate that while PP2A-B56α suppresses specific oncogenic pathways, B56α activation exacerbates PDAC proliferative phenotypes and decreases overall survival <i>in vivo</i> , potentially through increased epidermal growth factor receptor (EGFR) signaling. EGFR is a critical signaling node in PDAC as inhibition or loss of EGFR prevents KRAS-driven tumorigenesis and increased EGFR activity is associated with poor patient outcome. The activation of EGFR by PP2A-B56α is in part mediated through increased expression and processing of EGFR ligands, specifically amphiregulin, heparin-binding EGF-like growth factor (HB-EGF), and epiregulin. Furthermore, pharmacological PP2A activation in combination with EGFR inhibitors mitigates this signaling and increases cell death. Together, these studies implicate a previously undescribed non-canonical role for PP2A-B56α in EGFR signaling that contributes to PDAC progression.
BibTeX
@misc{pfeffer2025activation,
  author = {Claire M. Pfeffer and Sydney J. Clifford and Saadia A. Karim and Ella Rose D. Chianis and Brittany N. Heil and Lauren E. Gartenhaus and E. Kay and Garima Baral and Elizabeth G. Hoffman and Sagar M. Utturkar and Harish Kothandaraman and Whitney R. Smith-Kinnaman and Kasi Hansen and Emily A. Smith and Emily Porter and Fuping Zhang and Nadia A. Lanman and Jukka Westermarck and Emma H. Doud and Amber L. Mosley and Jennifer P. Morton and Brittany L. Allen-Petersen},
  title = {{Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDAC}},
  year = {2025},
  doi = {10.1101/2025.07.18.665598},
  howpublished = {bioRxiv},
}
Figure